From: Happy Oyster on
On Mon, 12 Oct 2009 22:30:21 -0700 (PDT), Jan Drew <jdrew63929(a)aol.com> wrote:

> Jan Drew <jdrew63...(a)aol.com> wrote:
>
>
>This thread is not about any bogspot.

Oh, really?



http://www.gavialliance.org/resources/home_1_noflash.jpg

http://www.gavialliance.org/media_centre/press_releases/2008_03_10_ug...

[*QUOTE*]
--------------------------------------------------------------------------
Deadly Disease Eliminated in Children under Five Years of Age in Uganda
Nearly 100 Percent Drop in Hib Meningitis as a Result of Widespread Vaccination

GENEVA, SWITZERLAND, 10 March 2008 - Hib meningitis has been virtually
eliminated in young children in Uganda just five years after the country
introduced Haemophilus influenzae type b (Hib) vaccine nationwide, according to
an independent study.

Haemophilus influenzae type b is a leading cause of pneumonia and meningitis, an
inflammation of the lining covering the brain and spinal cord. Each year, Hib
kills approximately 400,000 children under five years of age, most of them in
the developing world. It is also responsible for approximately three million
cases of serious illnesses resulting in long-term consequences such as deafness,
paralysis, mental retardation and learning disabilities. The positive results
are outlined in a study to be published in the April issue of The Bulletin of
the World Health Organization, an independent peer-reviewed international public
health journal. Advanced publication of the study can be found at
http://www.who.int/bulletin/publish_ahead_of_print/en/index.html

Upon monitoring occurrence of bacterial meningitis due to Hib between 2001 to
2006, the study&rsquo;s authors saw marked decline in the disease resulting from
implementation of a new vaccination program. Where monitored, the incidence rate
dropped by 85 percent within four years of vaccine introduction and fell to zero
in the fifth year. The authors estimate that Hib vaccine in the Ugandan
immunisation programme now prevents almost 30,000 cases of severe Hib disease
and 5,000 child deaths (under five years) annually, equivalent to the successful
control of measles in the country.

Funding for Hib vaccine is a major part of the GAVI Alliance's (formerly known
as the Global Alliance for Vaccines and Immunisation) programme support to
Uganda. With GAVI support, Uganda was able to introduce 16.5 million doses of
Hib vaccines nationwide from 2002 to 2006. The government chose to use what is
known as a pentavalent vaccine - a 5 in 1 injection that includes vaccines for
Hib as well as diphtheria, pertussis, tetanus, and hepatitis B.

"GAVI welcomes these extremely positive results" said Dr Julian Lob-Levyt,
Executive Secretary of the GAVI Alliance. "Thanks to the collaborative efforts
of the Ugandan Ministry of Health, the WHO, UNICEF and other partners, we can
applaud a true success in controlling this deadly disease that has too often
claimed so many lives."

Uganda was one of the first GAVI-eligible countries to adopt Hib vaccine,
preceding what is now a global trend. According to a recent report released by
WHO, the Centers for Disease Control and Prevention and the Hib Initiative,
between 2004 and 2007 the proportion of the 72 poorest countries eligible for
GAVI support using or approved to use Hib vaccine increased from 18 percent to
65 percent. In November, the GAVI board approved additional funding for Hib
vaccine, bringing the total number of countries with approved proposals to 44.

"This is excellent news for the future generations of Ugandanchildren. Uganda
has been afrontrunner in the Africa region in adopting this life-saving vaccine.
The leadership of early introducers such as Uganda, Kenyaand The Gambia
hasstronglyinfluencedthe decisions of many other countries in the region to
adoptHib vaccine. Today, 83% of the GAVI-eligible countries in Africa have now
included or will soon include Hib vaccine in their national immunization
programmes&rdquo; says Rana Hajjeh, Director of the Hib Initiative.

"We are proud of the results of this study. It's encouraging to know that these
kinds of interventions in Uganda and elsewhere are making a significant
contribution towards achieving the Millennium Development Goal of reducing
mortality in children less than 5 years of age," says Dr Sam Zaramba, Director
General of Uganda Ministry of Health "And GAVI's support was catalytic in
allowing us to tackle this disease quickly and efficiently."

The Government of Uganda recently committed national resources to procure Hib
vaccine for its infant immunisation programme, in line with the GAVI
co-financing policy.

"The introduction of Hib vaccine has now completely changed the epidemiology of
bacterial meningitis in Uganda, with elimination of meningitis due to Hib as a
public health problem" says Dr Kekitiinwa - Pediatrician at Mulago Hospital,in
Kampala Uganda, co-author of the study. "High quality surveillance has allowed
us to understand and monitor those trends to ensure the quality of the
immunisation programme, improve collaboration between clinicians and
laboratories and inform on drug susceptibility for the common organisms."

Although Hib vaccines for infants were first licensed in 1991 and have since
been widely adopted in industrialised countries, they have not been used
extensively in the developing world due to multiple barriers such as limited Hib
disease awareness, uncertainty about the burden of disease and concerns about
the financial and logistical implications of vaccine introduction. It took
almost 15 years for the Hib vaccine to be introduced in developing countries
after it was first licensed.

There are efforts underway to bridge this gap by reducing the number of years
developing countries have to wait to benefit from new vaccines. In 2007, a pilot
Advance Market Commitment (AMC) was announced, aiming at accelerating the
introduction of new vaccines in poor countries.

The Uganda results follow similar results found in Bangladesh, Kenya, Chile, the
Gambia, the United Kingdom, and United States. These studies have all concluded
that Hib vaccine cuts the incidence of disease by 88% or more within 3 to 5
years.

In July 2007, a study from Bangladesh showed that routine immunisation of
infants with a Hib conjugate vaccine prevented over one third of
life-threatening pneumonia cases and approximately 90% of Hib meningitis cases.

A Kenyan study in 2006 showed that the Hib vaccine cut the incidence of disease
by 88% within 3 years. The authors say that vaccinating against the bacterium
Haemophilus influenzae type b prevented approximately 3,370 Kenyan children from
being hospitalised in 2005.

The authors say that prior studies have shown that for every child with Hib
meningitis in developing countries, there may be 5 to 10 others with Hib-related
pneumonia, which is also preventable by vaccination. To achieve results more
quickly, the WHO position paper on Hib vaccine recommends that children at
highest risk, those under 2 years of age, be offered immunization at the time of
vaccine introduction.

The GAVI Alliance

The GAVI Alliance is a public-private partnership of major stakeholders in
vaccines and immunisation. It includes developing country and donor governments,
the World Health Organization, UNICEF, the World Bank, the vaccine industry in
both industrialised and developing countries, research and technical agencies,
NGOs, the Bill & Melinda Gates Foundation and other private philanthropists. WHO
projections show that GAVI support has prevented more than 2.9 million future
deaths by the end of 2007.

GAVI's efforts are critical to achieving the Millennium Development Goal on
child health, which calls for reducing childhood mortality by two thirds by
2015. Of the 10 million children who die before reaching their fifth birthday
every year, 2.5 million die from diseases that could be prevented with currently
available or new vaccines.

For more information, please visit: http://www.gavialliance.org

The Hib Initiative

In December 2005, the GAVI Alliance launched a $37 million program called the
Hib Initiative, which unites infectious disease experts from Johns Hopkins
Bloomberg School of Public Health, the London School of Hygiene and Tropical
Medicine, the U.S. Centers for Disease Control and Prevention (CDC), and WHO to
advance evidence-informed decision-making regarding the use of Hib vaccine in
the developing world. An estimated 3 million cases of Hib disease occur each
year in children under the age of 5 years, resulting in approximately 400,000
deaths. For

more information, please visit: http://www.hibaction.org

For more information, please contact:
GAVI Alliance:
Jeffrey Rowland, (Geneva)
+41 22 909 7165 office
+ 41 79 240 45 59 mobile
jrowland [bat] gavialliance.org
Carol Vieira (New York)
+1 (401) 714-0821 office
+1 (571) 723.2432 mobile
CVieira [bat] burnesscommunications.com
Photo requests:
Sandra Scolari
+41 22 909 6528 office
sscolari [bat] gavialliance.org

Michel Aublanc (Paris)
+33 6 08 71 97 95 mobile
michel.aublanc [bat] wanadoo.fr
Cathy Bartley (London)
+44 208 694 9138 office
+44 795 856 1671 mobile
cathy.bartley [bat] bartley-robbs.co.uk
Claudio Tanca(Rome)
+39 06 697 6661 office
+39 347 530 9256 mobile
ctanca [bat] apcoworldwide.com

B-roll:
Download at
http://www.gavialliance.org/media_centre/videos/broadcast/index.php

Hib Initiative:
Lois Privor-Dumm
+1 410 502 4292 office
+1 484 354 8054 mobile
lprivord [bat] jhsph.edu
--------------------------------------------------------------------------
[*/QUOTE*]

Vaccination saves lives!

--
Interview mit dem Autor der "Reimbibel"
Kultur und Wissen
Ausl�ser war der Besuch von Benedikt XVI. in Auschwitz-Birkenau
http://www.nrhz.de/flyer/beitrag.php?id=14183
From: Happy Oyster on
On Sun, 11 Oct 2009 20:54:25 -0700 (PDT), rpautrey2 <rpautrey2(a)gmail.com> wrote:

>Beast,
>
>Is that link affiliated with your 'Quackpot Cult'?
>

Ralph Paul Autrey, Jr. is a criminal stalker. The attorneys of state have
homework to do.
--
Interview mit dem Autor der "Reimbibel"
Kultur und Wissen
Ausl�ser war der Besuch von Benedikt XVI. in Auschwitz-Birkenau
http://www.nrhz.de/flyer/beitrag.php?id=14183
From: t on

"Mark Probert" <mark.probert(a)gmail.com> wrote in message
news:38b5ca71-c95b-468e-ad6f-3e099e70c24e(a)o36g2000vbl.googlegroups.com...
My point stands. Too bad you do not like it.


From: Mark Probert on
On Oct 13, 9:11 pm, "t" <tool...(a)gmail.com> wrote:
> "Mark Probert" <mark.prob...(a)gmail.com> wrote in message
>
> news:38b5ca71-c95b-468e-ad6f-3e099e70c24e(a)o36g2000vbl.googlegroups.com...
>  My point stands. Too bad you do not like it.

Your point can stand, sit, or dribbledown your leg, it is still
utterly meaningless. I have no need tyo disprove something that the
proponents, who had access to all of Hulda's so-called research, could
not prove works.

From: t on
Call it whatever you want, the fact is that you cannot or will not attempt
to prove your assertion. That would mean that you are only another blowhard.
By the way, the world will not miss you.
"Mark Probert" <mark.probert(a)gmail.com> wrote in message
news:3e883c68-22ed-4246-a6b4-3985b1951930(a)o36g2000vbl.googlegroups.com...
On Oct 13, 9:11 pm, "t" <tool...(a)gmail.com> wrote:
> "Mark Probert" <mark.prob...(a)gmail.com> wrote in message
>
> news:38b5ca71-c95b-468e-ad6f-3e099e70c24e(a)o36g2000vbl.googlegroups.com...
> My point stands. Too bad you do not like it.

Your point can stand, sit, or dribbledown your leg, it is still
utterly meaningless. I have no need tyo disprove something that the
proponents, who had access to all of Hulda's so-called research, could
not prove works.